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fracture risk for any fractures (AF), hip fractures (HF), vertebral fractures (VF), and
non-vertebral fractures (NVF) separately, controlling for patient characteristics,
insurance type, health care provider type, Charlson comorbidity index score, pre-
index bone mineral density test, medication use and fracture history. RESULTS:
Among the 3587 new TPTD users (mean age 68.9 years; 91% female), adjusted inci-
dence rates per 1000 patient years by fracture type (for persistence groups 1-6months,
7-12months, 13-18months, 19-24months)were: AF 103.09, 78.17, 72.68, 59.31; HF 6.87,
6.11, 4.30, 3.76; VF 26.29, 15.62, 11.55, 9.57; and NVF 70.90, 60.29, 60.24, 48.60. Fracture
risk was significantly higher for persistence 6 months versus 19-24 months in all
fracture models (OR1.75 [AF], 2.67 [VF], and 1.41 [NVF]), except for HF (OR1.95,
p0.078). Other significant risk factors included: older age (HF (OR1.06, p0.001) and
VF (OR1.04, p0.001); previous anticonvulsant use (VF (OR2.20, p0.001), VF
(OR1.79, p0.001)); previous immunosuppressant use (NVF (OR1.54, p0.013)); and
pre-index fracture (AF (OR1.37, p0.005); NVF (OR1.71, p0.001)). CONCLUSIONS:
Among US teriparatide patients, fracture incidence rates and fracture risk decreased
as persistence increased for any clinical, vertebral, and non-vertebral fractures.
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PERSISTENCE WITH BISPHOSPHONATE THERAPY AND RISK OF HIP FRACTURE
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OBJECTIVES: to investigate the association between persistence with bisphospho-
nates therapy and the risk of hip fracture in a large cohort of adult women.
METHODS: A retrospective cohort study using the database of Maccabi Healthcare
Services, a 2-million member health maintenance organization in Israel. Persis-
tence with bisphosphonates therapy was assessed by calculating the proportion of
days covered (PDC). Patients included women aged 60 years or above initiating an
oral bisphosphonates for osteoporosis between 2002 and 207. RESULTS: The inci-
dence density rate of hip fractures during study follow-up period was 4 per 1000
person-years among the 8741 patients meeting study eligibility criteria. We found
an inverse relation between persistence with bisphosphonates and hip fracture
rate. Women covered with bisphosphonates for at least 75% of the time, had a
hazard ration of 0.65 (95% confidence interval: 0.05-2.3) for hip fracture, compared
to women covered with bisphosphonates for less than 25% of the time..
CONCLUSIONS:We found a suggestive negative relation between persistence with
osteoporosis treatment and long term risk of hip fracture.
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THE PREVALENCE OF BONE FRACTURES IN OSTEOPOROSIS PATIENTS USING
PROTON PUMP INHIBITORS
Choi IS, McGuire M, Park HK, Suh DC
Rutgers University, Piscataway, NJ, USA
OBJECTIVES: To estimate the prevalence and risk factors associated with fracture
events in osteoporosis patients using proton pump inhibitor (PPI) therapy.
METHODS: This analysis utilized data from the 2001-2008 Medical Expenditure
Panel Surveys. Patients were identified if they were 50 years old, reported
having osteoporosis (ICD-9-CM code of 733 or clinical classification of 206). The
identified patients were classified into two groups depending on use of PPI.
Medications considered were osteoporosis medications (e.g., bisphosphanates,
hormone therapy, and raloxifene) and corticosteroids (excluding topical formu-
lations). Fractures were identified based on ICD-9-CM codes of 804-829. Preva-
lence of fractures was compared between two groups. Factors influencing risk of
fracture were identified through multivariable logistic regression after adjust-
ing for patient characteristics, use of medications, and comorbidities such as
heart disease, hypertension, nephropathy, depression, arthritis, epilepsy, dia-
betes, stroke, and cancer. RESULTS: We identified 4,979 patients with osteopo-
rosis, of which 970 were using PPIs and 4,009 patients were not. The majority of
the study patients were composed of females (91.4%) and non-smokers (89.6%).
Corticosteroids were used in 20.7% of the patients and osteoporosis medications
in 61.8% of patients. Bisphosphonates were the most commonly used agent in
49.2% of patients. Fractures were more prevalent in patients with PPI compared
to patients without (11.3% vs. 7.5%; p.003). Patients with PPI had a higher
likelihood of having a fracture than patients without PPI (OR1.53; p.009).
Other factors increasing risk of fractures were increasing age, heart disease,
hypertension, and stroke. CONCLUSIONS: PPI use in osteoporosis patients in-
creased the prevalence and risk of fractures. The results add to the growing body
of evidence supporting increased risk of fractures in osteoporosis patients
treated with a PPI. Additional research is recommended to investigate incidence
of fracture caused by use of PPI in osteoporosis patients.
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OBJECTIVES: Patientswith Rheumatoid Arthritis (RA) experience excess cardiovas-
cular (CVD) morbidity andmortality. RA puts patients at twice the risk for myocar-
dial infarction (MI) and stroke, younger patients being at higher risk.We investigate
the impact of RA on CVD morbidity in a high risk Medicaid managed care popula-
tion, largely female, African American, young adults, with baseline risk factors of
hypertension and diabetes. METHODS: Maryland Medicaid claims data for pa-
tients with diabetes and/or hypertension, from January 2001-June 2006 were
analyzed. Using exploratory analysis, we assessed the prevalence of RA and of
CVD, as well as the prevalence of CVD within the RA population. Logistic regres-
sion analysis was used to explore the joint impact of RA, demographics, hyper-
tension and diabetes on the likelihood of having a CVD event. RESULTS: The
prevalence RA was 2.2% among patients at high-risk for CVD. Patients with RA
were significantly older (mean age 49 vs. 34, p0.0001), largely females (80% vs.
64%, p0.0001) and non-African American (55% vs. 59%, p0.0001) than those
without RA. CVD prevalence was significantly higher in the RA population
among compared to the general population (37% vs. 17%). After adjusting for
demographics (age, gender, race) and risk factors (hypertension, diabetes), RA
significantly increased the likelihood of CVD events (OR: 1.539, 95% CI: 1.416-
1.674). In the adjusted model, hypertension (OR: 3.227) and diabetes (OR: 2.035)
also independently increased the likelihood of CVD events. CONCLUSIONS: We
found that RA independently increased cardiovascular risk by 1.5 times, in a Med-
icaid population with high baseline risk.
Muscular-Skeletal Disorders – Cost Studies
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THE BUDGET IMPACT OF LOWER GPA ADHERENCE IN PATIENTS WITH
CHRONIC NON-STEROIDAL AND COX-2 INHIBITOR USE
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OBJECTIVES: To evaluate the budget impact of adherence to concomitant gastro-
protective (GPA) therapy among patients using non-selective non-steroidals (ns-
NSAIDs) or COX-2 inhibitors (COXIBs) at high risk for NSAID-induced upper gastro-
intestinal (UGI) complications. Clinical guidelines recommend that patients at high
risk for UGI complications using ns-NSAIDs or COXIBs for arthritis pain manage-
ment should concomitantly take GPA; however, GPA use and adherence are often
low and associated with an increase in UGI events.METHODS: The impact of GPA
adherence was assessed using a budget impact model with a one-year time hori-
zon. UGI risk is a function of patient (age, previous ulcer history, concomitant low
dose aspirin use) and treatment (ns-NSAID or COXIB, concomitant GPA use and
adherence) characteristics. A mean GPA adherence rate of 51% was derived from
theMarketScan Research Databases, using a sample of patients50 years old with
at least 2 prescriptions for ns-NSAIDs or COXIBs from 2001 through 2007
(N738,248). Treatment-specific UGI event rates and costs were taken from the
literature for dyspepsia, symptomatic ulcers and UGI bleeding. Sensitivity analysis
was performed around the model inputs. RESULTS: In the base case analysis,
NSAID-induced UGI events are responsible for $9,328,857 in direct medical costs
annually in a hypothetical health plan with 100,000 members, where 21.6% of
patients are on chronic ns-NSAID or COXIB therapy for arthritis and 82% of these
patients are at increased risk of a UGI event due to age, previous ulcer history, or
both. Increasing GPA adherence to 75% decreases NSAID-induced UGI event costs
by $547,074, or -$0.45 per-member-per-month (PMPM) in a 100,000-member health
plan; reducing GPA adherence to 25% increases these costs by $737,834 ($0.62
PMPM). CONCLUSIONS: GPA adherence has a strong impact on the cost associated
with NSAID-induced UGI events. This finding was consistent throughout sensitiv-
ity analyses varying risk factors and costs of UGI events.
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COST CONSEQUENCE OF COLCHICINE APPROVAL IN THE MEDICAID PROGRAMS
IN THE UNITED STATES
Zhang YJ, Kelton C, Guo JJ
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OBJECTIVES: In 2009, the price of colchicine, an anti-gout agent that is also used to
treat familial Mediterranean fever, skyrocketed, surprising physicians, patients,
and payers. Objectives are to (1) determine the cost consequence to the U.S. Med-
icaid programs of this price rise and (2) explain why it occurred. METHODS: Med-
icaid drug utilization data were used to identify all colchicine products from 2000
quarter 1 through 2010 quarter 1. The first five digits of each product’s NDC code
were used to identify the manufacturer. A retrospective, descriptive analysis was
conducted to determine the trends of colchicine utilization (prescriptions and tab-
lets), spending (in 2009 US$), and reimbursement per tablet as a proxy for price.
RESULTS:Colchicine utilization byMedicaid enrollees increased from 2000 to 2005,
reaching 417,000 prescriptions (18million tablets, $4.5million). FollowingMedicare
Part D and the movement of dual eligibles from Medicaid to Medicare, Medicaid
colchicine utilization dropped 72% in terms of number of prescriptions. The aver-
age spending for colchicine not marketed by URL Pharma increased from $0.27 per
tablet in 2000–2009 to $0.35 in the first quarter of 2010 (30% increase), while the
Colcrys® price (URL’s branded drug) rose from $0.29 in 2000–2008 to $3.79 in 2009–
2010 (12-fold increase). It is estimated that an additional $21million could be added
to Medicaid spending if all patients on single-ingredient colchicine treatment
switched to Colcrys®. CONCLUSIONS: The rise in price is an unintended conse-
quence of a drug-safety initiative launched in June 2006 by the U.S. Food and Drug
Administration (FDA) to phase out unapproved drugs, including single-ingredient
oral colchicines. Meanwhile, the FDA granted approval to URL Pharma in July 2009,
inadvertently creating a monopoly in the anti-gout market. If additional drugs are
not approved to stimulate competition, a substantial financial burden will be
placed on patients and taxpayers.
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APPLYING THE STRATIFIED PROPENSITY SCORE MATCHING METHOD WHEN
ESTIMATING HEALTH CARE COSTS OF RHEUMATOID ARTHRITIS PATIENTS
Baser O, Xie L
STATinMED Research, Ann Arbor, MI, USA
OBJECTIVES: To apply the stratified propensity score matching technique to esti-
mate the healthcare costs of rheumatoid arthritis (RA) patients. METHODS: Con-
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tinuously eligible adult patientswith confirmed diagnoses of RA between June 2004
and June 2009 were included in the study. Patients were either new to tumor ne-
crosis factor (TNF) therapy and subsequently switched to another anti-TNF, or
escalated their TNF dose. The difference in total and RA-related healthcare costs
between switchers and escalators 1 year after the switch/dose escalation were
estimated using the stratified propensity score matching method with five sub-
classes. The differences in patient, clinical, and demographic characteristics were
controlled as well. RESULTS: After risk adjustment using stratified propensity
score matching, the difference between switchers and dose escalators is $2,905 in
total healthcare costs, $8,577 in outpatient costs, $630 in inpatient costs, $10,851 in
pharmacy costs, $2,294 in RA-related healthcare costs, $8,410 in RA-related outpa-
tient costs, $36 in RA-related inpatient costs, and $10,668 in RA-related pharmacy
costs. CONCLUSIONS: After adjusting for patient, clinical and demographic char-
acteristics using the stratified propensity score matching method, patients who
switched to another anti-TNF incurred more total and RA-related healthcare costs
compared to patients who escalated their dose. The cost burden is mainly attrib-
uted to pharmacy costs.
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OBJECTIVES: Compare direct (healthcare, i.e., medical and drug) and indirect
(workloss) utilization and costs between privately insured U.S. employees with
Dupuytren’s Contracture (DC) and demographically matched controls without DC.
METHODS: Employees ages 18-64 with 1 DC diagnosis (ICD-9-CM: 728.6, 718.44)
between 1/1/2000-3/31/2009 were selected from a de-identified, privately insured
claims database (N12,000,000). The index date was defined as themost recent DC
diagnosis with continuous eligibility for 6months prior (baseline period) and 1 year
after (study period) the diagnosis date. Employees with DC were matched 1:1 on
age, region, gender, and index date to controls without DC, Peyronie’s, or Ledder-
hose disease diagnoses in their claims histories. Descriptive analyses compared
demographic characteristics, comorbidities, resource utilization, direct costs (re-
imbursements to providers for medical and prescription drugs), and indirect costs
(disability and medically related absenteeism) inflated to 2009 dollars. RESULTS:
1,406 DC employees (mean age 49 years) with matched controls met the inclusion
criteria. DC employees comparedwith controls had significantly (all p0.05) higher
baseline comorbidities, including hyperlipidemia (21.1% vs. 15.6%), hypothyroid-
ism (3.5% vs. 2.0%), cancer (3.1% vs. 1.5%), and diabetes with/ without chronic
complications (2.2%/7.5% vs. 0.4%/3.6%). During the study period, DC employees
had significantly (all p0.01) higher rates of inpatient stays (7.7% vs. 5.3%), Emer-
gency Department visits (19.8% vs. 13.9%), outpatient visits (100.0% vs. 78.4%),
physical therapy visits (30.2% vs. 7.2%), any prescription use (85.0% vs. 69.2%), and
notably prescription opioid use (35.1% vs. 14.2%) as well as higher mean workloss
days (14.2 vs. 7.3). DC employees had on average significantly (all p0.01) higher
annual direct costs ($5,974 vs. $3,175), indirect costs ($2,737 vs. $1,309), and total
costs ($8,712 vs. $4,485) compared with controls during the study period.
CONCLUSIONS: Employees with DC had higher comorbidity rates, utilization, and
direct and indirect costs compared with demographically matched controls.
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OBJECTIVES: Osteoporosis-related fractures are common despite the availability of
treatments. Little evidence exists on fracture costs using recent US administrative
claims data. We estimated incremental direct medical costs of closed hip, vertebral,
andnon-hipnon-vertebral (NHNV) fracturesamong female commercially insuredand
Medicare patients. METHODS: Women over age 50 with a hip, vertebral, or NHNV
(wrist/forearm, tibia/fibula, pelvis, humerus, andclavicle) fracturebetween July1, 2005
and December 31, 2007 were identified using the MarketScan Commercial and Medi-
care Supplemental Databases. Eligible patients had continuous enrollment 6 months
before and 12 months after their index fracture with no fracture in the pre-index
period. Fracture patients were matched 1:1 to fracture-free controls based on sex,
region, age, index year, and diagnostic cluster score ranges. Incremental costs for
fracture patients were estimated during the 12-month post-index period by fracture
type and payer (commercial or Medicare). The distribution of cost components was
assessed afterweighting by fracture type. Adjusted incremental fracture-related costs
were estimated using a generalized linear model with log link, controlling for pre-
period total costs andconfounding conditions.RESULTS:Weidentified90,396women
with fracture (17,528 hip, 12,514 vertebral, 60,354 NHNV). Unadjusted incremental
costs for hip, vertebral, andNHNV fractureswere $34,735, $21,914, and $9,726, respec-
tively, among commercially insured patients, and $25,350, $11,102, and $10,233, re-
spectively, amongMedicarepatients. Inpatient costswerehighest (47.9%), followedby
outpatient services (28.2%), long term care/nursing home services (20.3%), and emer-
gency roomvisits (3.6%). Resultswere consistent aftermultivariate analyses.Adjusted
incremental annualmedical costs of hip, vertebral, andNHNV fractureswere $34,944,
$21,965, and $10,047, respectively, among commercially insured patients and $25,098,
$11,300, and $10,337, respectively, among Medicare patients. CONCLUSIONS: Osteo-
porosis-related fractures are associatedwith substantial directmedical costs that dif-
fer by fracture type and payer. Fracture prevention can reduce health care costs asso-
ciated with osteoporosis.
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OBJECTIVES: Osteoarthritis (OA) affects nearly 14% of US adults and only few re-
cent studies have assessed the economic burden of this common condition. The
objective of this study was to compare direct healthcare costs of OA patients and
similar patients without the condition to determine the cost burden associated
with OA. METHODS: De-identified insurance claims from the Thomson Reuters
MarketScan® Databases were used to retrospectively analyze direct healthcare
costs of adult OA patients and matched controls. Patients with an OA claim (ICD-
9-CM: 715.xx) in 2007 were matched 1:1 to demographically similar patients with-
out OA claims. Costs were assessed over 12 months. Generalized linear regression
was used to control for baseline demographic and clinical differences between
cohorts that remained after matching. RESULTS: The OA sample (n258,237) was
predominantly female (64%), with a mean age of 67 years. About half (52%) were
newly diagnosedwith OA in 2007; the remainder had evidence of the disease in the
preceding year. Total mean adjusted costs for OA patients were $18,435 annually
(95% CI $18,318-$18,560), compared to $7,494 (95% CI $7,425-$7,557) for controls
without OA.More OApatients than controlswere hospitalized for any cause during
the 12-month study period (30.4% vs. 9.5%). Corresponding inpatient costs were
$6,668, on average, for OA patients (95%CI $6,587-$6,744) and $1,756 (95%CI $1,717-
$1,794) for controls. In comparison, mean outpatient pharmacy costs were $3,213
(95%CI $3,195-$3,233) for OApatients and $2,245 (95%CI $2,229-$2,262) for controls.
CONCLUSIONS: The direct healthcare costs of OA patients were over two times
higher than those of similar patients without the condition. Higher inpatient costs
among OA patients were the primary driver of the cost difference. Higher inpatient
costs among OA patients should prompt clinicians to pay attention to associated
comorbid illnesses.
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AND TOP FIVE CHRONIC DISEASES
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OBJECTIVES: Rheumatoid Arthritis (RA) may result in work productivity loss and
high overall healthcare costs for employers. However, the impact on health-risks is
not well studied. This study compares risk, absenteeism, and medical/pharmacy
costs for individuals with RA and 5 commonly managed chronic conditions. We
compared health-risks, lost productivity, and total direct healthcare costs among
individuals with Rheumatoid Arthritis (RA) and five most prevalent chronic
conditions. METHODS: Health-risk information and self-reported illness days us-
ing health-risk assessment (HRA) data were examined and direct Healthcare costs
(medical and pharmacy) using claims data for employees, retirees, and their adult
dependents of a large self-insured employer were compared from 2002-2006
among individuals with RA and five most prevalent chronic conditions; asthma,
coronary artery disease/congestive heart failure (CAD/CHF), diabetes, hyperten-
sion, chronic obstructive pulmonary disease (COPD). RESULTS: 129 individuals
with RA were identified. The RA cohort had moderate health-risk score (2.7/5)
which was comparable to individuals with asthma (2.8/5), CHF (2.9), hypertension
(2.6) and lower than diabetes (3.2/5) and COPD (3.4/5). Whereas, higher proportion
(34.1%) of individuals with RA had 5 illness days per year as compared with
individuals with asthma (31.8%), CAD/CHF (25.9%), hypertension (20.4%), diabetes
(28.4%), and COPD (33%). Annual direct healthcare costs were also higher for indi-
viduals with RA ($30,897) as compared to individuals with asthma ($25,814), CAD/
CHF ($22,916), hypertension ($18,632), and diabetes ($28,035), and lower as com-
pared to individualswith COPD ($38,839).CONCLUSIONS: Individualswith RAhave
similar health-risks but higher illness days, and direct healthcare costs as com-
pared to the individuals with five most prevalent chronic conditions. RA is a high
costs and lost productivity driver for employers. Population health based programs
that engage employees in appropriately managing their chronic conditions can
help employers reduce health-risks, improve productivity, and may help reduce
healthcare costs as well.
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COST OF RHEUMATOID ARTHRITIS PATIENTS RECEIVING TNF-ANTAGONIST
THERAPY FROM THE KOREA NATIONAL HEALTH INSURANCE CLAIMS
DATABASE
Park SJ, Lee EK
SookMyung Women’s University, Seoul, South Korea
OBJECTIVES: To analyze characteristics and to estimate costs of rheumatoid ar-
thritis(RA) patients treated with TNF antagonist using the Korea national health
insurance(KNHI) claims database between 2007 and 2009 from insurer’s
perspective.METHODS: RA patients were identified as adults ( age of 19) who had
at least one KNHI recordwith a diagnosis of RA (ICD-10 codes: M05-06) in 2007, 2008
and 2009. TNF antagonist naïve patients were defined as RA patients who didn’t
have any claim record for a TNF antagonist during window period but who had
records between Jul. 1.2007 and Dec. 31.2008. Socio-demographic and clinical char-
acteristics, healthcare utilization, and costswere assessed for following 12months.
Direct medical costs included the total costs for medical services and drug costs
except uninsured medical expenses. Multiple logistic regression was used to cal-
culate the effects of several factors on the total costs. All statistical analyses were
performed with SAS/STAT® 9.1. RESULTS: 48.9% of patients with at least one inpa-
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